ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company
focused on the generation and development of antibody therapeutics
targeting toxic misfolded proteins in neurodegenerative diseases
such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis
(ALS) and multiple system atrophy (MSA), today announced that
preclinical data supporting the potential role of its lead product
candidate, PMN310, as a treatment for AD will be highlighted in an
oral presentation at the 4th International Conference on Cognitive
& Behavioral Neurosciences (ICBN) taking place from September
12-13, 2024 in Lisbon, Portugal.
A large body of evidence indicates that the most pathogenic
species of amyloid-beta (Aß) in AD consists of soluble toxic
oligomers as opposed to insoluble fibrils and monomers. The ability
of a therapeutic antibody to target toxic amyloid-beta oligomers
(AßO) without being diverted by binding to competing non-toxic
species has the potential to result in greater efficacy. As a next
generation antibody, PMN310 is a therapeutic candidate designed to
target toxic oligomers more selectively.
“The data being shared at ICBN further support PMN310 as a
potential treatment for AD due to its enhanced selectivity for
toxic oligomers” stated Johanne Kaplan, Ph.D., Chief Development
Officer of ProMIS Neurosciences and platform presenter.
“Importantly, the ability of PMN310 to avoid interaction with
plaque and vascular deposits of amyloid-beta could potentially
reduce the risk of amyloid-related imaging abnormalities, or ARIA,
a dose-limiting toxicity associated with plaque-binding
antibodies.”
In the studies, the binding of PMN310 and other Aß-directed
antibodies to a toxic oligomer-enriched low molecular fraction of
brain extract from AD patients was evaluated by surface plasmon
resonance, with and without monomer competition. The results
indicated that PMN310 showed little or no interaction with monomers
and was among the least impacted by excess monomer competition in
binding to toxic oligomers in AD brain extract. Additionally,
PMN310 did not bind to Aß plaque or vascular deposits as determined
by immunohistochemistry. These results highlight how PMN310
distinguishes itself from other Aß-directed antibodies and may
potentially provide an improved product profile with enhanced
efficacy.
Details of the oral presentation are as
follows:
Title: Distinguishing between amyloid-beta
directed antibodies: Ability of PMN310 to target toxic oligomers
despite competing species Date/Time of Virtual
Presentation: Friday, September 13 at 2:00pm WEST (6:00am
PT / 9:00am ET)Authors: Johanne Kaplan, Ebrima
Gibbs, Juliane Coutts, Beibei Zhao, Neil R. Cashman
The slide presentation is available on the Posters and
Publications page of the Company’s website at
www.promisneurosciences.com.
In July 2024, ProMIS Neurosciences reported positive topline
data from the first four cohorts in its first-in-human Phase 1a
clinical trial of PMN310, demonstrating that it met objectives for
tolerability, safety and pharmacokinetics. The Company expects to
report topline results from all five cohorts [in the coming months]
and is on-track to advance PMN310 into a Phase 1b study in the
fourth quarter of 2024.
About PMN310PMN310 is a
humanized monoclonal antibody (mAb) designed and developed based on
its selectivity for soluble amyloid beta oligomers (AβOs), which
ProMIS believes are the most toxic and pathogenic form of Aβ,
relative to Aβ monomers and amyloid plaque. Soluble AβOs have been
observed to be potent neurotoxins that bind to neurons, inhibit
synaptic function and induce neurodegeneration. By selectively
targeting toxic soluble AβOs, PMN310 aims to directly address the
growing body of evidence suggesting that they represent a primary
underlying cause of the neurodegenerative process in Alzheimer’s
disease.
About ProMIS Neurosciences
Inc.
ProMIS Neurosciences Inc. is a clinical stage biotechnology
company focused on generating and developing antibody therapeutics
selectively targeting toxic misfolded proteins in neurodegenerative
diseases such as Alzheimer’s disease (AD), amyotrophic lateral
sclerosis (ALS) and multiple system atrophy (MSA). The Company’s
proprietary target discovery engine applies a thermodynamic,
computational discovery platform - ProMIS™ and Collective
Coordinates - to predict novel targets known as Disease Specific
Epitopes on the molecular surface of misfolded proteins. Using this
unique approach, the Company is developing novel antibody
therapeutics for AD, ALS and MSA. ProMIS has offices in Toronto,
Ontario and Cambridge, Massachusetts.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Certain information in
this news release constitutes forward-looking statements and
forward-looking information (collectively, “forward-looking
information”) within the meaning of applicable securities laws. In
some cases, but not necessarily in all cases, forward-looking
information can be identified by the use of forward-looking
terminology such as “plans”, “excited to”, “targets”, “expects” or
“does not expect”, “is expected”, “an opportunity exists”, “is
positioned”, “estimates”, “intends”, “assumes”, “anticipates” or
“does not anticipate” or “believes”, or variations of such words
and phrases or state that certain actions, events or results
“may”, “could”, “would”, “might”, “will” or “will be taken”,
“occur” or “be achieved”. In addition, any statements that refer
to expectations, projections or other characterizations of future
events or circumstances contain forward-looking information.
Specifically, this news release contains forward-looking
information relating to the Company’s preclinical data, novel
vaccine approach to target toxic oligomers and the potential
implications thereof, the Company's expectations regarding its
clinical development of its lead product, PMN310, for AD, and the
Company’s plans to announce additional results and advance into a
Phase 1b multiple ascending dose study in AD patients. Statements
containing forward-looking information are not historical facts but
instead represent management's current expectations, estimates and
projections regarding the future of our business, future plans,
strategies, projections, anticipated events and trends, the
economy and other future conditions. Forward-looking information is
necessarily based on a number of opinions, assumptions and
estimates that, while considered reasonable by the Company as of
the date of this news release, are subject to known and unknown
risks, uncertainties and assumptions and other factors that may
cause the actual results, level of activity, performance or
achievements to be materially different from those expressed or
implied by such forward-looking information, including, but not
limited to, the risk that the results of nonclinical studies and
early clinical trials are not necessarily predictive of future
results with PMN310, the Company’s ability to fund its operations
and continue as a going concern, its accumulated deficit and the
expectation for continued losses and future financial results.
Important factors that could cause actual results to differ
materially from those indicated in the forward-looking information
include, among others, the factors discussed throughout the “Risk
Factors” section of the Company's most recently filed Annual Report
on Form 10-K for the year ended December 31, 2023 and in its
subsequent filings filed with the United States Securities and
Exchange Commission. Except as required by applicable securities
laws, the Company undertakes no obligation to publicly update any
forward-looking information, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
For further information:
Visit us at www.promisneurosciences.com
Please submit media inquiries to
info@promisneurosciences.com.
For Investor Relations, please
contact: Precision AQ (formerly Stern IR)Anne Marie
Fields, Managing Directorannemarie.fields@precisionaq.comTel.
212-362-1200
ProMIS Neurosciences (NASDAQ:PMN)
Historical Stock Chart
From Aug 2024 to Sep 2024
ProMIS Neurosciences (NASDAQ:PMN)
Historical Stock Chart
From Sep 2023 to Sep 2024